DIA

AstraZeneca

AstraZeneca acquires Pearl Therapeutics

Tuesday, June 11, 2013 01:02 PM

AstraZeneca has acquired Pearl Therapeutics, a privately held company focused on the development of inhaled small-molecule therapeutics for respiratory disease.

More... »

ACRP Certification Program - July 31st

AstraZeneca awarded grant by The Michael J. Fox Foundation

Thursday, May 30, 2013 03:50 PM

The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded global biopharmaceutical AstraZeneca (AZ) a grant to support research on levodopa-induced dyskinesias (LID), a complication of therapies commonly used to reduce Parkinson's disease symptoms.

More... »

CRF Health – eCOA Forum

AstraZeneca to acquire Omthera, NDA-ready novel dyslipidemia treatment

Wednesday, May 29, 2013 11:35 AM

Global biopharmaceutical company, AstraZeneca, has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, N.J., focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.

More... »

AltheRx raises $15M, names Jim Bennethum CEO, appoints new board of directors

Monday, May 6, 2013 10:41 AM

AltheRx Pharmaceuticals, a privately-held clinical development company, announced a restructuring that includes a $15 million financing, the appointment of Jim Bennethum as CEO, and the appointment of a new board of directors.

More... »

BIND Therapeutics, AstraZeneca ink cancer nanomedicine agreement

Monday, April 22, 2013 03:17 PM

BIND Therapeutics, a clinical-stage biopharmaceutical company, and AstraZeneca have entered into a strategic collaboration to develop and commercialize an Accurin, a targeted and programmable cancer nanomedicine from BIND's medicinal nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.

More... »

Horizon Discovery, AstraZeneca collaborate on oncology drug discovery

Monday, April 22, 2013 01:54 PM

Horizon Discovery, a provider of research tools to support translational genomics research, and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon's first-in-class kinase target program, HD-001, as a means of developing novel therapies for multiple cancer types.

More... »

AstraZeneca touts top-line results from OSKIRA-1 phase III study of fostamatinib in RA

Friday, April 5, 2013 12:33 PM

AstraZeneca released top-line results of OSKIRA-1, a phase III study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). OSKIRA-1 had two primary endpoints: assessing signs and symptoms of RA as measured by ACR20 response rates, and an X-ray endpoint known as mTSS (modified Total Sharp Score).

More... »

MedImmune aquires Alphacore Pharma

Wednesday, April 3, 2013 02:20 PM

MedImmune, AstraZeneca’s global biologics R&D arm, has acquired AlphaCore Pharma, an Ann Arbor, Mich.-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.

More... »

AstraZeneca, Moderna Therapeutics to develop pioneering messenger RNA Therapeutics

Friday, March 22, 2013 10:51 AM

AstraZeneca, a global biopharmaceutical company, has formed an exclusive agreement with Moderna Therapeutics, a Cambridge-Mass.-based biopharmaceutical company, to discover, develop and commercialize pioneering messenger RNA therapeutics for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer.

More... »

AstraZeneca to establish strategic R&D centers, cut or relocate 4,100 workers

Monday, March 18, 2013 02:12 PM

Global biopharmaceutical company AstraZeneca announced plans to invest in strategic R&D centers in the U.K., the U.S. and Sweden to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation.

More... »

Almac Clinical Services
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

June 17

New CISCRP study finds patient perceptions of trial participation safety, motives greatly improved

PwC: Volume and value of pharma, diagnostics deals soar in first quarter, as CRO sector waits on sidelines

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

Operating environment spurs out-of-the-box ideas
High cost, low success rates drive some sponsors to new monitoring, protocol design, patient-centric initiatives

Private equity interest in CROs could lead to more IPOs
Now flush with cash, many PE investors readying to cash out

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs